NCT01455103View on ClinicalTrials.gov

Phase 1 Biomarker Study of Anti-PDL-1 in Advanced Melanoma

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 30, 2011

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions
Stage III or IV Melanoma
Interventions
BIOLOGICAL

BMS-936559 (Anti-PD-L1)

Solution, Intravenous infusion, 1 mg/kg, Every 2 weeks, Up to 2 years, depending on response

BIOLOGICAL

BMS-936559 (Anti-PD-L1)

Solution, Intravenous infusion, 3 mg/kg, Every 2 weeks, Up to 2 years, depending on response

BIOLOGICAL

BMS-936559 (Anti-PD-L1)

Solution, Intravenous infusion, 10 mg/kg, Every 2 weeks, Up to 2 years, depending on response

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY